Overview

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Status:
NOT_YET_RECRUITING
Trial end date:
2026-11-22
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
Phase:
PHASE1
Details
Lead Sponsor:
Hangzhou Sciwind Biosciences Co., Ltd.